A lot depends on a big unknown right now: Federal policy. If the new Attorney General pursues enforcement of the Controlled Substances Act, it's likely to damper investment in general, especially in non-medical cannabis companies. So, cultivation and retail stores may struggle to find investors in states where non-medical (adult use) measures are in place.
It's unlikely that there will be enforcement, if any, against medical cannabis providers, but it could dampen interest, especially in companies focused on edibles or high potency extracts, which could see regulation.
Absent these concerns, I think that companies that help lower the cost of production or increase regulatory compliance are good areas of focus in any environment.